logo.jpg
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
October 15, 2021 13:05 ET | Genmab A/S
Media ReleaseCopenhagen, Denmark, October 15, 2021 Janssen-Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe...
logo.jpg
Grant of Restricted Stock Units and Warrants to Employees in Genmab
October 07, 2021 14:55 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; October 7, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 18,689 restricted stock units and 21,537...
logo.jpg
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
October 01, 2021 08:00 ET | Genmab A/S
Media Release Copenhagen, Denmark, October 1, 2021 Mini-oral presentation highlighting data from first-in-human trial evaluating investigational bispecific antibody DuoBody®-CD40×4-1BB...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 21, 2021 14:22 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 21, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The...
logo.jpg
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
September 20, 2021 17:00 ET | Genmab A/S
TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer CellsNew Monotherapy Approved for Use in a Cancer with Limited Treatment Options ...
logo.jpg
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
September 19, 2021 11:30 ET | Genmab A/S
Media Release Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment Tisotumab Vedotin in Combination with Pembrolizumab Showed...
logo.jpg
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
September 09, 2021 07:00 ET | Genmab A/S
Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell...
logo.jpg
Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
August 27, 2021 04:42 ET | Genmab A/S
Media ReleaseCopenhagen, Denmark, 27 August, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 17, 2021 14:51 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 17, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants. The...
logo.jpg
Genmab Announces Financial Results for the First Half of 2021
August 11, 2021 11:01 ET | Genmab A/S
August 11, 2021; Copenhagen, Denmark; Interim Report for the First Half of 2021 Highlights The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application...